Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis

Daclatasvir-based Treatment Regimens for Hepatitis C Virus Infection: A Systematic Review and Meta-Analysis has published recently in Hepat Mon by Alavian et al: Abstract Context: Direct acting antivirals (DAAs) have recently emerged as a promising therapeutic regimen for the treatment of hepatitis C virus (HCV) infection, which is a major…

Read More

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline

Recommendations for the Clinical Management of Hepatitis C in Iran: A Consensus-Based National Guideline has published recently in Hepat Mon by Alavian et al:  Abstract Context: Hepatitis C virus (HCV) infection is a major public health issue worldwide, including Iran. The new direct-acting antiviral agents (DAAs) with high efficacy have…

Read More

New recommendations in the updated WHO guidelines for the screening, care and treatment of persons with chronic hepatitis C infection

Publication date: February 2016 Authors:WHO Background The World Health Organization (WHO) issued the first Guidelines for the screening, care and treatment of persons with hepatitis C infection in 2014. Since then, several new medicines for the treatment of HCV infection have been introduced. These medicines are transforming the treatment of…

Read More

Hepatitis C Treatment and Cirrhosis

April 4, 2016 In October 2015, the FDA issued this disturbing headline: “FDA Drug Safety Communication: FDA warns of serious liver injury risk with hepatitis C treatments Viekira Pak and Technivie.” The problem with that headline, is it needlessly scared patients who were taking Viekira Pak and Technivie, when in…

Read More

Harvoni is Safe and Effective in Seniors With Hepatitis C

March 30, 2016 Gilead Sciences’ Harvoni (ledipasvir/sofosbuvir) is safe and effective in treating hepatitis C virus (HCV) among individuals age 65 and up, Reuters Health reports. Publishing their findings in the journal Hepatology, researchers analyzed data on 2,293 people with hep C enrolled in four Phase III trials of Harvoni.…

Read More

Mathematical Model Predicts Who Can Stop Hepatitis C Treatment Early

March 28, 2016 Researchers have developed a mathematical model that can help determine if individuals can stop hepatitis C virus (HCV) treatment early, a move that would save a considerable amount of money. Publishing their findings in the Journal of Hepatology, investigators analyzed 58 people with hep C receiving 12…

Read More

Please Check HBs Ag Before Chemotherapy

Mar 18, 2016 Gastroenterologists Have Suboptimal Hepatitis B Virus Screening Rates in Patients Receiving Immunosuppressive Therapy. Paul S1, Shuja A2, Tam I3, Kim EM3, Kang S4, Kapulsky L4, Viveiros K3, Lee H5. Abstract BACKGROUND AND AIMS: Hepatitis B reactivation in patients undergoing immunosuppressive therapy can lead to liver failure and…

Read More

Treatment options of patients with chronic hepatitis C who have failed prior therapy

February 26, 2016 Abbreviations DAA direct-acting antiviral PI protease inhibitor RAV resistance-associated variant SVR sustained virological response The development of direct-acting antivirals (DAAs) has provided physicians with a toolbox to achieve near-universal cure of hepatitis C. Combinations of nucleoside polymerase inhibitors (sofosbuvir), nonnucleoside polymerase inhibitors (dasabuvir), protease inhibitors (PIs; simeprevir,…

Read More